Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib.
Alexandros RampotasLuke Carter-BrzezinskiTim C SomervailleJames ForryanFotios P PanitsasClaire N HarrisonRuth WitherallAndrew J InnesLouise WallisNauman M ButtBethan PsailaAdam J MeadMatthew CarterAnna L GodfreyHeather LaingMamta GargSebastian FrancisJoanne EwingChun Huat TehHannah B CowanPeter DyerConal McConvilleFrances WadelinSahra AliAndrew McGregorElizabeth KulakovDonal P McLornanJonathan LambertPublished in: Blood (2023)
Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
Keyphrases
- soft tissue
- newly diagnosed
- wound healing
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- chronic kidney disease
- prognostic factors
- emergency department
- cardiovascular disease
- risk factors
- climate change
- coronary artery disease
- risk assessment
- young adults
- human health
- patient reported
- free survival
- basal cell carcinoma
- childhood cancer
- case control
- glycemic control